Hematology

Latest News

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, demonstrating efficacy with no new safety signals.

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers. | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

While improvements were seen in non-relapse mortality in CLL throughout the decade, the researchers observed no differences in overall survival or progression-free survival. | Image credit: LASZLO - stock.adobe.com
New Era of CLL Treatments Brings Changes to Use of HSCT

June 9th 2025

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com
Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Gut Microbiome Could Play Key Role in Multiple Myeloma
July 10th 2020

Gut Microbiome Could Play Key Role in Multiple Myeloma

Jared Kaltwasser
Scientists do not yet have a full understanding of how multiple myeloma develops, but a new article suggests the gut microbiome is one factor that may play a role.
MM Progression, Treatment Do Not Appear to Impact COVID-19 Mortality, Study Finds
July 4th 2020

MM Progression, Treatment Do Not Appear to Impact COVID-19 Mortality, Study Finds

Jared Kaltwasser
A new study that looked at a cohort of 58 patients with multiple myeloma (MM) who contracted COVID-19 found the disease itself does not appear to be linked with higher mortality when these individuals are hospitalized.
CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain
July 2nd 2020

CAR T-Cell Therapies Show Promise for Multiple Myeloma, but Hurdles Remain

Jared Kaltwasser
There are promising signs that chimeric antigen receptor (CAR) T-cell therapies might lead to meaningful advances in the therapy of multiple myeloma. However, investigators will first need to clear a number of key hurdles.
MRD Should Be More Widely Used in Clinical Care of MM, Report Argues
June 26th 2020

MRD Should Be More Widely Used in Clinical Care of MM, Report Argues

Jared Kaltwasser
Minimal residual disease (MRD) status has been shown to be a better indicator of the prognosis of a patient with multiple myeloma (MM) than “complete remission.” Yet, it’s still not widely used in the clinic. A new article examines the problem.
What We're Reading: Bayer Settles Cancer Claims; Census Data Show Demographic Shift; Suit Alleges Regeneron Kickbacks
June 25th 2020

What We're Reading: Bayer Settles Cancer Claims; Census Data Show Demographic Shift; Suit Alleges Regeneron Kickbacks

AJMC Staff
Bayer AG agreed to settle the majority of claims alleging its product Roundup causes blood cancer; Census Bureau data show a historic demographic shift; a federal lawsuit claims Regeneron funneled millions of dollars to a charity.
What Are the Barriers to Choosing Wisely in Hematology Care?
June 19th 2020

What Are the Barriers to Choosing Wisely in Hematology Care?

Allison Inserro
The American Society of Hematology has adopted 10 of the recommendations from Choosing Wisely to encourage more high-value care, but barriers to adoption remain.
Multiple Myeloma Treatment Priorities Vary Among Patients, Clinicians, and Caregivers
June 18th 2020

Multiple Myeloma Treatment Priorities Vary Among Patients, Clinicians, and Caregivers

Jared Kaltwasser
A new survey finds patients, caregivers, and medical professionals have somewhat different priorities when considering treatment options for multiple myeloma.
New Method Enables Smartphone-Based Diagnosis of Sickle Cell Disease
June 14th 2020

New Method Enables Smartphone-Based Diagnosis of Sickle Cell Disease

Jared Kaltwasser
Patients with sickle cell disease who do not receive treatment can die from the disease, but diagnostic resources are scarce in some parts of the world where the disease is most prevalent. A new smartphone-based method could change that.
Induction Therapy Optimal for Transplant-Eligible Patients With Multiple Myeloma
June 11th 2020

Induction Therapy Optimal for Transplant-Eligible Patients With Multiple Myeloma

Jared Kaltwasser
A new large randomized trial indicates induction therapy including lenalidomide is optimal in patients with multiple myeloma who are transplant-eligible. Maintenance with lenalidomide was preferable to observation alone following transplant.
Smoldering MM Study Suggests Deeper Links to Metabolic Syndromes
June 7th 2020

Smoldering MM Study Suggests Deeper Links to Metabolic Syndromes

Jared Kaltwasser
Patients with multiple myeloma (MM) face higher risks of certain metabolic syndromes, but new research suggests those risks exist even in patients with smoldering MM.
Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care
June 2nd 2020

Smoldering Multiple Myeloma Research Promising but Not Yet Translatable to Change in Care

Jared Kaltwasser
As investigators have learned more about how to diagnose and categorize smoldering multiple myeloma (SMM), a new review article argues there’s insufficient data to evolve beyond a close observation approach.
Multiple Myeloma With CNS Relapse a Challenging Puzzle for Clinicians
May 30th 2020

Multiple Myeloma With CNS Relapse a Challenging Puzzle for Clinicians

Jared Kaltwasser
A new review article outlining research into multiple myeloma with central nervous system (CNS) involvement explains the many reasons it is difficult to diagnose and treat the disease.
Patient Perception of Sickle Cell Care Differs by Acute vs Nonacute Settings
May 29th 2020

Patient Perception of Sickle Cell Care Differs by Acute vs Nonacute Settings

Allison Inserro
Helping patients find a clinician who is experienced with sickle cell disease can have many positive benefits, a new study noted.
Minimal Residual Disease Status Appears to Correlate With Patient-Centered Outcomes in Those With Hematological Malignancies
May 29th 2020

Minimal Residual Disease Status Appears to Correlate With Patient-Centered Outcomes in Those With Hematological Malignancies

Jared Kaltwasser
Clinicians use the presence or absence of minimal residual disease as a metric by which to judge the efficacy of therapy in patients with hematological malignancies. A new review article interrogates whether that approach aligns with patient-centered outcomes.
Long-term Survival Increasing in Patients With Hematologic Malignancies
May 29th 2020

Long-term Survival Increasing in Patients With Hematologic Malignancies

Jared Kaltwasser
New advances in therapy have led to better long-term survival rates in patients with hematologic malignancies, but there are some caveats to the good news.
AML, Multiple Myeloma Can Be Treated Simultaneously, According to Case Study
May 16th 2020

AML, Multiple Myeloma Can Be Treated Simultaneously, According to Case Study

Jared Kaltwasser
It’s rare for a patient to be diagnosed with both acute myeloid leukemia and multiple myeloma at the same time, but a new case study suggests there are options to treat both diseases at the same time in such cases.
Chronic Transfusion Therapy for Sickle Cell Burdens Patients, Families, Study Says
May 15th 2020

Chronic Transfusion Therapy for Sickle Cell Burdens Patients, Families, Study Says

Jared Kaltwasser
A new study based on interviews with families and patients undergoing chronic transfusion therapy for sickle cell disease finds that the therapy affects the families in ways that extend beyond health.
Whites With Multiple Myeloma, Vitamin D Deficiency Have Lower Survival Rates
May 10th 2020

Whites With Multiple Myeloma, Vitamin D Deficiency Have Lower Survival Rates

Jared Kaltwasser
New data suggests white patients who are deficient in vitamin D have lower rates of survival when diagnosed with multiple myeloma. The phenomenon was not seen, however, in African American patients.
What Are the Health Care Access and Quality Factors in Multiple Myeloma Survival?
May 5th 2020

What Are the Health Care Access and Quality Factors in Multiple Myeloma Survival?

Jared Kaltwasser
New research suggests disparities in incidence and survival rates in multiple myeloma may have a lot to do with healthcare quality and access to care.
Extramedullary Disease in MM Tough to Treat, Even With Newer Therapies, Study Says
April 30th 2020

Extramedullary Disease in MM Tough to Treat, Even With Newer Therapies, Study Says

AJMC Staff
Outcomes were worse for patients with multiple myeloma (MM) and extramedullary disease, and the authors said their findings indicate that evaluation of extramedullary response using imaging is needed in this group.
COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows
April 29th 2020

COVID-19 Increases Overall Risk of Death, Complications in Patients With Cancer, Study Shows

Maggie L. Shaw
Recent study results show that patients with cancer who develop coronavirus disease 2019 (COVID-19) are far more likely to die than those who develop COVID-10 but do not have cancer. Patients being treated with immunotherapy appear to be at particularly high risk.
Report Describes Patient With MM, COVID-19 Treated Successfully With Tocilizumab
April 25th 2020

Report Describes Patient With MM, COVID-19 Treated Successfully With Tocilizumab

Jared Kaltwasser
A new article outlining the experience of a patient with a history of multiple myeloma (MM) who contracted coronavirus disease 2019 (COVID-19) shows the interleukin-6 receptor inhibitor tocilizumab was an effective therapy.
What Is the Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting?
April 25th 2020

What Is the Economic Value of Receiving CAR T-Cell Therapy in an Outpatient Setting?

Gianna Melillo
Chimeric antigen receptor (CAR) T-cell therapy has been shown to improve health-related quality of life in patients with relapsed/refractory diffuse large B-cell lymphoma (LBCL). Currently, CAR T-cell therapies are primarily administered in inpatient settings. In a study published in JAMA Network Open, researchers found CAR T-cell therapy administered to patients with relapsed or refractory LBCL in outpatient settings was associated with lower estimated overall costs.
What We're Reading: Public Fears Worst of Pandemic; Blood Clotting and COVID-19; VA Facilities Struggle
April 23rd 2020

What We're Reading: Public Fears Worst of Pandemic; Blood Clotting and COVID-19; VA Facilities Struggle

AJMC Staff
A new poll conducted by the Kaiser Family Foundation shows a majority of Americans fear the worst of the coronavirus disease 2019 (COVID-19) pandemic is yet to come; reports of blood clots in patients with COVID-19 raise concerns; Veterans' Affairs medical facilities are struggling to cope with the pandemic.
Dr Elisabet Manasanch: Identifying Patients With Smoldering Multiple Myeloma Remains an Unmet Need
April 16th 2020

Dr Elisabet Manasanch: Identifying Patients With Smoldering Multiple Myeloma Remains an Unmet Need

Identifying patients with smoldering multiple myeloma is difficult as they often do not have any symptoms, but we could still do a much better job than what we are currently implementing, said Elisabet Manasanch, MD, assistant professor in the Department of Lymphoma/Myeloma and Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.
Mitochondrial Pathways Not the Culprit in Bortezomib Neurotoxicity, Study Finds
April 15th 2020

Mitochondrial Pathways Not the Culprit in Bortezomib Neurotoxicity, Study Finds

Jared Kaltwasser
New research evaluates bortezomib and carfilzomib in an attempt to understand the causes of neurotoxicity in the former. They found the mitochondrial pathway is likely not the problem.
FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy
April 4th 2020

FDA's Revised Blood Donation Guidance for Gay Men Still Courts Controversy

Maggie L. Shaw
The FDA has announced a relaxing of its restrictions on gay men being allowed to donate blood, in light of the coronavirus disease 2019 pandemic. Instead of 1 year, if a male has had sex with another male, he need only wait 3 months to donate blood.
Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds
March 29th 2020

Carfilzomib Improves Prognosis in Patients With High-Risk Multiple Myeloma, Study Finds

Jared Kaltwasser
Patients with high-risk multiple myeloma tend to have significantly worse prognoses compared to those in the standard-risk category. A new study offers a potential solution.
Site Logo
March 23rd 2020

Why Donate Blood During the Coronavirus Crisis? Because I Can

Maggie L. Shaw
I am type O negative. There are only 7% of us in the United States. My blood is red gold, if you will. I am a universal donor, which means that my blood can go to anyone.
Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants
March 22nd 2020

Study Examines Fixed-Duration Therapy in Patients With MM Ineligible for Transplants

Jared Kaltwasser
Newly diagnosed patients with multiple myeloma (MM) who are transplant-ineligible sometimes plan fixed-duration therapy to improve their quality of life. A new study examines the impact of that approach.
<1
...
67891011121314
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo